Immunohistochemical expression of p16 in desmoplastic melanoma

Journal of Cutaneous Pathology

Volumn 40, Issue 9, 2013, Pages 796-800

  Blokhin, Elena ^a,b   Pulitzer, Melissa ^a   Busam, Klaus J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Ackermann Academy of Dermatopathology   (United States)

Author keywords

immunohistochemical method; malignant melanoma; p16 protein

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; P16 PROTEIN, HUMAN; PROTEIN P16; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; BIOSYNTHESIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENE EXPRESSION REGULATION; HUMAN; IMMUNOHISTOCHEMICAL METHOD; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; METABOLISM; MIDDLE AGED; NEVUS; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; SKIN TUMOR; VERY ELDERLY;

IMMUNOHISTOCHEMICAL METHOD; MALIGNANT MELANOMA; P16 PROTEIN;

ADULT; AGED; AGED, 80 AND OVER; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; MIDDLE AGED; NEOPLASM PROTEINS; NEVUS, EPITHELIOID AND SPINDLE CELL; SKIN NEOPLASMS;

EID: 84883053120     PISSN: 03036987     EISSN: 16000560     Source Type: Journal    
DOI: 10.1111/cup.12186     Document Type: Article

References (13)

1. Busam KJ,. Desmoplastic melanoma. Clin Lab Med 2011; 31: 321.
2. Barr RJ, Morales RV, Graham JH,. Desmoplastic nevus: a distinct histologic variant of mixed spindle cell and epithelioid cell nevus. Cancer 1980; 46: 557.
3. Harris GR, Shea CR, Horenstein MG, Reed JA, Burchette JL Jr, Prieto VG,. Desmoplastic (sclerotic) nevus: an underrecognized entity that resembles dermatofibroma and desmoplastic melanoma. Am J Surg Pathol 1999; 23: 786.
4. Hilliard NJ, Krahl D, Sellheyer K,. p16 expression differentiates between desmoplastic Spitz nevus and desmoplastic melanoma. J Cutan Pathol 2009; 36: 753.
5. Kucher C, Zhang PJ, Pasha T, et al. Expression of Melan-A and Ki-67 in desmoplastic melanoma and desmoplastic nevi. Am J Dermatopathol 2004; 26: 452.
6. Busam KJ, Chen YT, Old LJ, et al. Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma. Am J Surg Pathol 1998; 22: 976.
7. Granter SR, Weilbaecher KN, Quigley C, Fletcher CD, Fisher DE,. Microphthalmia transcription factor: not a sensitive or specific marker for the diagnosis of desmoplastic melanoma and spindle cell (non-desmoplastic) melanoma. Am J Dermatopathol 2001; 23: 185.
8. Gerami P, Beilfuss B, Haghighat Z, Fang Y, Jhanwar S, Busam KJ,. Fluorescence in situ hybridization as an ancillary method for the distinction of desmoplastic melanomas from sclerosing melanocytic nevi. J Cutan Pathol 2011; 38: 329.
9. Tran TP, Titus-Ernstoff L, Perry AE, Ernstoff MS, Newsham IF,. Alteration of chromosome 9p21 and/or p16 in benign and dysplastic nevi suggests a role in early melanoma progression (United States). Cancer Causes Control 2002; 13: 675.
10. Piccinin S, Doglioni C, Maestro R, et al. p16/CDKN2 and CDK4 gene mutations in sporadic melanoma development and progression. Int J Cancer 1997; 74: 26.
11. Pavey SJ, Cummings MC, Whiteman DC, et al. Loss of p16 expression is associated with histological features of melanoma invasion. Melanoma Res 2002; 12: 539.
12. Al Dhaybi R, Agoumi M, Gagne I, McCuaig C, Powell J, Kokta V,. p16 expression: a marker of differentiation between childhood malignant melanomas and Spitz nevi. J Am Acad Dermatol 2011; 65: 357.
13. Mason A, Wititsuwannakul J, Klump VR, Lott J, Lazova R,. Expression of p16 alone does not differentiate between Spitz nevi and Spitzoid melanoma. J Cutan Pathol 2012; 39: 1062.